Grand River Aseptic Manufacturing, a portfolio company of Arlington Capital Partners, has promoted Denis Johnson to Chief Executive Officer, effective September 1, 2025.

Johnson has served as President of GRAM since March 31, 2025. In this new role, he will lead GRAM’s next phase of growth, driving strategic expansion, operational excellence, and deepened client engagement in the aseptic manufacturing space.

Derek Hennecke, who has served as CEO since September 15, 2024, will return to GRAM’s Board of Directors.

Experience

Johnson brings extensive life sciences leadership and manufacturing experience to this role, including significant prior sterile fill-finish experience. His previous roles include Head of Global Manufacturing and Technical Operations at Biogen as well as leadership roles at Catalent, Boston Scientific and Johnson & Johnson. He started his career in the U.S. Army managing logistics and operations. 

“I am honored to step into the role of CEO at GRAM,” Johnson remarked. “As we celebrate the company’s 15th anniversary, I look forward to working with our talented team to expand our capabilities, enhance our service delivery, and uphold the high standards our clients expect.”